• 23 JAN 17
    • 0

    New Contract Shows Promise for Spotting Malignancies

    Researchers looking for better methods for detecting cancer faster may have found a new way to supercharge a standard CT scan for doing so. Through the use of a new tracer drug that’s placed in an iodine-infused bubble, researchers have been able to pinpoint suspect masses easier and more effectively. The results have even extended to masses that are in difficult-to-diagnose locations, such as the liver.

    While still very much in the study phase, the new imaging protocol has shown a great deal of promise. A recent study into its effectiveness involved the use of 13 canines that were suspected to have cancer. Researchers found the contrast agent was able to make lesions more readily visible for a longer period of time than other agents. The findings are especially exciting because they may indicate a better way has been found to confirm or deny the presence of elusive tumors sooner. This, in turn, could lead to faster, more effective interventions down the road.
    The new tracer must undergo more testing and trials before it might be made available for use on humans. Researchers, however, are hopeful its effectiveness will stand up to more rigorous scrutiny.

    Courtesy of early screening tests and strong awareness campaigns many forms of cancer that were once deemed incredibly deadly have high survival rates today. Advances in testing protocols are a critical piece of the puzzle in beating this disease once and for all. By offering the potential to find tumors in elusive spots more readily, this breakthrough may someday provide a way to more effectively treat a variety of cancers.

    Cancer is a concern for everyone. To find out more about personal risks and what can be done to address them, speak with a healthcare provider. It is recommended that everyone, regardless of age, undergo at least a routine annual checkup during which cancer screening may play a role based on personal risks for various forms of this disease.

    Leave a reply →